These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38588973)

  • 1. Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres.
    Shields RK; Yücel E; Turzhitsky V; Merchant S; Min JS; Watanabe AH
    J Glob Antimicrob Resist; 2024 Jun; 37():190-194. PubMed ID: 38588973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Heo YA
    Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
    Smith JR; Rybak JM; Claeys KC
    Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
    Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
    Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
    Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
    Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
    Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
    Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
    J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
    Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
    Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
    Ghazi IM; El Nekidy WS; Asay R; Fimognari P; Knarr A; Awad M
    PLoS One; 2020; 15(5):e0233335. PubMed ID: 32421696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia.
    Chaftari AM; Dagher H; Hachem R; Jiang Y; Lamie P; Wilson Dib R; John T; Haddad A; Philip A; Alii S; Mulanovich P; Yuan Y; Chaftari P; Raad I
    J Antimicrob Chemother; 2024 Oct; 79(10):2543-2553. PubMed ID: 39092963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
    Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
    J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
    Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
    Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B
    Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imipenem-cilastatin-relebactam used to treat ventilator-associated pneumonia developing after infection with SARS-CoV-2].
    Zahornacký O; Porubčin Š; Rovňáková A; Jarčuška P
    Klin Mikrobiol Infekc Lek; 2022 Mar; 28(1):18-21. PubMed ID: 36183413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.